Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2036-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of
CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion
regimen with fludarabine and/or cyclophosphamide